Datapoint: Gilenya Patent Upheld in Appeals Court

Novartis scored a major patent victory for its multiple sclerosis drug, Gilenya, this week. A federal appeals court on Tuesday upheld a dosage regimen patent for the sphingosine 1-phosphate receptor modulator, granting Novartis a permanent injunction against generic challenger HEC Pharma. The patent is currently set to expire in 2027. For the treatment of multiple sclerosis, 25% of all insured lives have unrestricted access to Gilenya under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/5/2022

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 20

Datapoint: Pfizer Scores Atopic Dermatitis Approval for Cibinqo

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 19

Datapoint: Centene Settles With New Hampshire in Medicaid Pharmacy Dispute

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
January 18

Datapoint: BCBSND Selected for North Dakota Medicaid Expansion

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today